Integrating cannabis into clinical cancer care

Current Oncology

Volumn 23, Issue , 2016, Pages S8-S14

  Abrams, D I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anorexia; Cannabinoids; Cannabis; Nausea; Pain; Symptom management

Indexed keywords

ALIZAPRIDE; CANNABIDIOL; CANNABIS; CHLORPROMAZINE; DOMPERIDONE; DRONABINOL; HALOPERIDOL; LEVONANTRADOL; MEDICAL CANNABIS; MEGESTROL; METOCLOPRAMIDE; NABILONE; NABIXIMOLS; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; THIETHYLPERAZINE;

ANALGESIC ACTIVITY; ANOREXIA; ANTIEMETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL (TOPIC); DEPRESSION; GOVERNMENT; HUMAN; INSOMNIA; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC);

EID: 84961644338     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.23.3099     Document Type: Article

References (58)

1. Mosbergen D. Now We Know What Killed the Ancient “Ice Princess”, and Why She Had That Marijuana [Web article]. New York, NY: The Huffington Post; 2014. [Available at: http://www.huffingtonpost.com/2014/10/16/siberian-iceprincess-cancer-cannabis_n_5993052.html; cited 19 December 2015]
2. Rappold RS. Legalize Medical Marijuana, Doctors Say in Survey [Web article]. Atlanta, GA: WebMD; 2014. [Available at: http://www.webmd.com/news/breaking-news/marijuana-on-main-street/20140225/webmd-marijuana-survey-web; cited 19 December 2015]
3. Russo EB. Taming thc: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163:1344-64.
4. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potent ial ant icancer drug. Br J Clin Pharmacol 2013;75:303-12.
5. Rog DJ, Nurmikko TJ, Fride T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19.
6. Duran M, Perez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010;70:656-63.
7. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of thc:cbd extract and thc extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39:167-78.
8. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014;47:166-73.
9. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Pharmacology. lxxix. Cannabinoid receptors and their ligands: beyond cb1 and cb2. Pharmacol Rev 2010;62:588-631.
10. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2456-73.
11. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735-44.
12. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009;10:1353-68.
13. Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA 2015;314:2172-81.
14. Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review or randomized controlled trials. Can Fam Physician 2015;61:e372-81.
15. Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain 2015;16:1221-32.
16. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain 2015;16:616-27.
17. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid cb1 and cb2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152:765-77.
18. Khasabova IA, Khasabov S, Paz, Harding-Rose C, Simone DA, Seybold VS. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012;32:7091-101.
19. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 2014;171:636-45.
20. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014;47:166-73.
21. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-24.
22. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (thc), morphine, and a thc-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88.
23. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008;9:254-64.
24. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, gradeddose trial. J Pain 2012;13:438-49.
25. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011;90:844-51.
26. Ware MA. Clearing the smoke around medical marijuana. Clin Pharmacol Ther 2011;90:769-71.
27. 9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 2015;14:8711-21.
28. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979;91:819-24.
29. Chang AE, Shiling DJ, Stillman RC, et al. A prospective evaluation of delta-9-tetracannabinol as an antiemetic in patients receiving Adriamycin and Cytoxan chemotherapy. Cancer 1981;47:1746-51.
30. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25.
31. Duran M, Perez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010;70:656-63.
32. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21.
33. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008;17:431-43.
34. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015;11:CD009464.
35. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Ver. 2.2015. Fort Washington, PA: nccn; 2015. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (free registrat ion required); cited 19 December 2015]
36. Strasser F, Luftner D, Possinger K, et al. on behalf of the Cannabis-In-Cachexia-Study-Group. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase iii, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394-400.
37. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-73.
38. Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011;22:2086-93.
39. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with hiv/aids. Cochrane Database Syst Rev 2013;4:CD005175.
40. Holloway A. Did ancient Siberian princess use cannabis to cope with breast cancer? [Web article]. London, UK: Ancient Origins; 2014. [Available at: http://www.ancient-origins.net/news-history-archaeology/did-ancient-siberian-princessuse-cannabis-cope-breast-cancer-002207;cited 19 December 2015]
41. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597-602.
42. Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Guzman M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 2004;47:315-23.
43. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012;12:436-44.
44. McAllister SD, Soroceanu L, Desprez PY. The antitumour activity of plant-derived non-psychoactive cannabinoids. J Neuroimmune Pharmacol 2015;10:255-67.
45. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potent ial ant icancer drug. Br J Clin Pharmacol 2013;75:303-12.
46. Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget 2014;5:5852-72.
47. Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther 2015;97:575-86.
48. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci). Cannabis and Cannabinoids—for health professionals (PDQ) [Web page]. Bethesda, MD: nci; 2015. [Available at: http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq; cited 11 December 2015]
49. Donadelli M, Dando I, Zaniboni T, et al. Gemcitabine/ cannabinoid combination triggers autophagy in pancreatic cancer cells through a ros-mediated mechanism. Cell Death Dis 2011;2:e152.
50. Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10:90-103.
51. Scott KA, Daigleish AG, Liu WM. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 2014;13:2955-67.
52. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003;11:137-43.
53. Bowles DW, O’Bryant CL, Camidge R, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012;83:1-10.
54. Kramer JL. Medical marijuana for cancer. CA Cancer J Clin 2015;65:109-22.
55. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharamcotherapy 2013;3:195-209.
56. Engels FK, de Jong FA, Sparreboom A, et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007;12:291-300.
57. Bostwick JM, Reisfield G M, DuPont RL. Medicinal use of marijuana. N Engl J Med 2013;368:866-8.
58. Adler JN, Colbert JA. Clinical decisions. Medicinal use of marijuana—polling results. N Engl J Med 2013;368:e30.